Roberto Sainti

Roberto Sainti

Healthcare Finance Expert
Roberto Sainti is an expert in healthcare finance, logistics, and investments. His content covers a wide range of topics, including the impact of healthcare logistics on hospital finances, cost-saving strategies through optimized supply chain strategies, and the economics of last-mile delivery in healthcare, among others. Roberto’s publications provide in-depth insights to his audience, alongside practical advice to facilitate implementation. 
Health Insurance Now Costs More Than the Mortgage
Business Health Insurance Now Costs More Than the Mortgage

For a growing number of self-employed Americans and their families, the most significant monthly expense is no longer the roof over their heads but the staggering price of staying healthy. This new financial reality has transformed health insurance from a routine budget item into a financial burden

What to Do When You Have No Health Insurance?
Business What to Do When You Have No Health Insurance?

Navigating the American healthcare landscape without insurance can feel like an impossible challenge, especially with policy shifts expected to leave millions more without coverage. To shed light on this pressing issue, we're speaking with a leading expert in health insurance policy and

For GLP-1s to Work, Medicare Must Cover Nutrition
Business For GLP-1s to Work, Medicare Must Cover Nutrition

The recent expansion of Medicare to cover GLP-1 agonist drugs for weight management has been widely hailed as a landmark achievement in public health, offering millions of Americans access to transformative treatments for obesity and related cardiometabolic conditions. However, this policy

Review of Affordable Surgical Instruments
Business Review of Affordable Surgical Instruments

The relentless pressure on healthcare budgets has forced procurement teams to navigate a complex landscape where the line between fiscal responsibility and uncompromising patient safety is finer than ever. In this environment, the traditional reliance on legacy brands for surgical instruments is

Why Is US Healthcare in Serious Condition?
Business Why Is US Healthcare in Serious Condition?

For a system that commands trillions of dollars in annual spending and pioneers global medical breakthroughs, the American healthcare apparatus is paradoxically failing to keep its own population healthy and financially secure. This sprawling, complex industry, a cornerstone of the national

Constraint Is Driving Global Healthcare Innovation
Business Constraint Is Driving Global Healthcare Innovation

The long-held assumption that the most advanced healthcare solutions originate exclusively in the world’s wealthiest research hospitals has quietly begun to crumble. For decades, the global health landscape operated on a top-down model, where innovation developed in resource-rich environments was l

Health Freedom vs. Healthcare Affordability: A Comparative Analysis
Business Health Freedom vs. Healthcare Affordability: A Comparative Analysis

The American healthcare debate has pivoted from a familiar tug-of-war over insurance plans to a profound clash of ideologies that pits the pursuit of personal liberty against the stark reality of economic survival. As the 2026 midterm elections approach, two competing visions are vying for the

J.P. Morgan Week Sparks a Biotech Financing Frenzy
Business J.P. Morgan Week Sparks a Biotech Financing Frenzy

The cascade of nine and ten-figure financing rounds unveiled during the J.P. Morgan Healthcare Conference week signals a dramatic revitalization of investor appetite, injecting billions of dollars into a biotech sector poised to translate this new capital into the next generation of therapies. This

How Do Medicaid Cuts Threaten Everyone's Care?
Business How Do Medicaid Cuts Threaten Everyone's Care?

At the helm of L.A. Care, the nation’s largest public health plan, Martha Santana-Chin oversees the well-being of over 2.2 million people. But for her, this work is not just professional; it is deeply personal. As a child of Mexican immigrants, she and her family relied on Medi-Cal, C

AbbVie Bets $650M on a New Dual-Action Cancer Drug
Business AbbVie Bets $650M on a New Dual-Action Cancer Drug

A Strategic Push into Next-Generation Oncology In a decisive move to bolster its cancer treatment portfolio, pharmaceutical giant AbbVie has committed $650 million upfront for the global rights to a promising new drug from Chinese biotech firm RemeGen. The deal, which could eventually reach over $5

Loading
Latest Articles

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later